<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S315 IS: Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD–CARE) Amendments of 2013</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-02-13</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 315</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130213">February 13, 2013</action-date>
			<action-desc><sponsor name-id="S311">Ms. Klobuchar</sponsor> (for
			 herself, <cosponsor name-id="S318">Mr. Wicker</cosponsor>,
			 <cosponsor name-id="S313">Mr. Sanders</cosponsor>, <cosponsor name-id="S252">Ms. Collins</cosponsor>, <cosponsor name-id="S306">Mr.
			 Menendez</cosponsor>, <cosponsor name-id="S305">Mr. Isakson</cosponsor>,
			 <cosponsor name-id="S182">Ms. Mikulski</cosponsor>, <cosponsor name-id="S057">Mr. Leahy</cosponsor>, <cosponsor name-id="S166">Mr.
			 Lautenberg</cosponsor>, and <cosponsor name-id="S282">Mr. Nelson</cosponsor>)
			 introduced the following bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To reauthorize and extend the Paul D. Wellstone Muscular
		  Dystrophy Community Assistance, Research, and Education Amendments of
		  2008.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short
			 title</header><text display-inline="no-display-inline">This Act may be cited as
			 the <quote><short-title>Paul D. Wellstone Muscular
			 Dystrophy Community Assistance, Research and Education (MD–CARE) Amendments of
			 2013</short-title></quote>.</text>
		</section><section id="id581F78AA84A147BE9CF76EB18B025C5A"><enum>2.</enum><header>Initiative
			 through the Director of the National Institutes of Health</header><text display-inline="no-display-inline">Section 404E of the Public Health Service
			 Act (<external-xref legal-doc="usc" parsable-cite="usc/42/283g">42 U.S.C. 283g</external-xref>) is amended—</text>
			<paragraph id="id3DE1CABC80C6429787F13440C64B1E0F"><enum>(1)</enum><text>in subsection
			 (a)(1)—</text>
				<subparagraph id="id43A765B52D6241D8A302B8AABEE228A7"><enum>(A)</enum><text>by striking
			 <quote>Muscoskeletal</quote> and inserting <quote>Musculoskeletal</quote>;
			 and</text>
				</subparagraph><subparagraph id="idEDAE97DD85C144219AD3F34B509624DF"><enum>(B)</enum><text>by inserting
			 <quote>Becker, myotonic, facioscapulohumeral muscular dystrophy (referred to in
			 this section as <quote>FSHD</quote>), Congenital muscular dystrophy,
			 Limb-girdle muscular dystrophy,</quote> after <quote>Duchenne,</quote>;</text>
				</subparagraph></paragraph><paragraph id="id4112B7F73B53415A8FD09149F8F6ED94"><enum>(2)</enum><text>in subsection
			 (b)—</text>
				<subparagraph id="id7F103BE460B64143BA335B42C5DE6095"><enum>(A)</enum><text>in paragraph (2),
			 by inserting <quote>cardiac and pulmonary function,</quote> after
			 <quote>imaging, genetics,</quote>; and</text>
				</subparagraph><subparagraph id="id494C83E6CF8145699ECC2B80D1C3F2EF"><enum>(B)</enum><text>in paragraph (3),
			 by inserting <quote>and sharing of data</quote> after <quote>regular
			 communication</quote>;</text>
				</subparagraph></paragraph><paragraph id="id619A55AD1CD1465D8A37AEDF94BC482C"><enum>(3)</enum><text>in subsection
			 (d)—</text>
				<subparagraph id="id180BF36F79034FDC86676EE8FBDE035E"><enum>(A)</enum><text>in paragraph
			 (2)—</text>
					<clause id="id6D7D27F77DE8486086CC6A0CEAA2D17A"><enum>(i)</enum><text>in
			 the matter preceding subparagraph (A), by striking <quote>15</quote> and
			 inserting <quote>18</quote>; and</text>
					</clause><clause id="id17430C7762FE4FF79A054B5DA144432A"><enum>(ii)</enum><text>in
			 subparagraph (A), by striking <quote>children with muscular dystrophy, such as
			 the Department of Education</quote> and inserting <quote>children and adults
			 with muscular dystrophy, such as the Department of Education, the Social
			 Security Administration, the United States Administration for Community
			 Living</quote>; and</text>
					</clause></subparagraph><subparagraph id="idF4AD6C3C7F854D6E8EF82E82A056E07A"><enum>(B)</enum><text>in paragraph
			 (4)(B), by inserting <quote>, and shall meet no less than two times per
			 calendar year</quote> before the period;</text>
				</subparagraph></paragraph><paragraph id="id3717CEBB6E1A4CD6B4F1384C071C7A6B"><enum>(4)</enum><text>in subsection
			 (e)—</text>
				<subparagraph id="idAC295BF6BA584D0AAE8FFC015450524F"><enum>(A)</enum><text>in paragraph
			 (1)—</text>
					<clause id="idB28E9D32DC114195A327A76C982E6422"><enum>(i)</enum><text>in
			 the matter preceding subparagraph (A), by striking <quote>through the national
			 research institutes</quote> and inserting <quote>through the represented
			 Federal agencies</quote>; and</text>
					</clause><clause id="id007A2AEEE1EE469C87F44DD9C830A0FE"><enum>(ii)</enum><text>in
			 subparagraph (A), by striking <quote>and rehabilitative issues, including
			 studies of the impact of such diseases in rural and underserved
			 communities</quote> and inserting <quote>public resources, and rehabilitative
			 issues, including studies of the impact of such diseases in rural and
			 underserved communities, health economic studies to demonstrate the
			 cost-effectiveness of providing independent living resources and support to
			 patients with various forms of muscular dystrophy, and studies to determine
			 optimal clinical care interventions for adults with various forms of muscular
			 dystrophy</quote>; and</text>
					</clause></subparagraph><subparagraph id="idBC2EC35B6D8843ACA69124BCE1381EE4"><enum>(B)</enum><text>in paragraph (2),
			 by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="idEE57AF0D0BF746C39A3FD5ABF6232118" style="OLC">
						<subparagraph id="idBEE723C8D37242EABD6A6CB7786FBF6C"><enum>(F)</enum><text>The development
				of clinical interventions to improve the health of adults with various forms of
				muscular dystrophy.</text>
						</subparagraph><after-quoted-block>;
				and</after-quoted-block></quoted-block>
				</subparagraph></paragraph><paragraph id="id1DB06F73BE2E471C87F5E67AF9AA5A8F"><enum>(5)</enum><text>in subsection
			 (g), by striking <quote>for the various forms of muscular dystrophy by
			 prioritizing the achievement of the goals related to this topic in the plan
			 under subsection (e)(1)</quote> and inserting <quote>and shall, not later than
			 6 months after the date of enactment of the <short-title>Paul D. Wellstone Muscular Dystrophy Community Assistance,
			 Research and Education (MD–CARE) Amendments of 2013</short-title>, in
			 coordination with appropriate Federal agencies, including relevant offices
			 within the Food and Drug Administration and supported by the National
			 Institutes of Health and Department of Defense, develop a plan to expedite the
			 evaluation and approval of emerging therapies and personalized medicines that
			 have the potential to decrease fatal disease progression across the various
			 forms of muscular dystrophy</quote>.</text>
			</paragraph></section><section id="idAD043BB8F6B64662A8A67FFF532FF566"><enum>3.</enum><header>Surveillance and
			 research regarding muscular dystrophy</header><text display-inline="no-display-inline">Section 317Q of the Public Health Service
			 Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-18">42 U.S.C. 247b–18</external-xref>) is amended—</text>
			<paragraph id="idDCD19290E7C94234B73F1BBB05336CA1"><enum>(1)</enum><text>in the second
			 sentence of subsection (b), by inserting before the period the following:
			 <quote>and ensure that the program captures data from different racial and
			 ethnic populations, and that such data are made publicly available to
			 investigators conducting public or private research on muscular
			 dystrophy</quote>; and</text>
			</paragraph><paragraph id="idFFE28E6A79FD412496F5D2B9F677F7F7"><enum>(2)</enum><text>in subsection
			 (c), by adding at the end the following: <quote>The Secretary shall also foster
			 ongoing engagement and collaboration between the surveillance program and
			 centers of excellence.</quote>.</text>
			</paragraph></section><section id="idF1C2981E43074836AB06CB5CBBAE6A0B"><enum>4.</enum><header>Information and
			 education</header><text display-inline="no-display-inline">Section 5(c) of the
			 Muscular Dystrophy Community Assistance, Research and Education Amendments of
			 2001 (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-19">42 U.S.C. 247b–19(c)</external-xref>) is amended by adding at the end the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="id157B58D72DC64C10B9DE9F7B32CC5691" style="OLC">
				<paragraph id="id2D5DDF586D4F48AF988A44AF9ED31D39"><enum>(4)</enum><text>Update and widely
				disseminate existing Duchenne-Becker muscular dystrophy care considerations for
				pediatric patients, develop and widely disseminate Duchenne-Becker muscular
				dystrophy care considerations for adult patients, and develop and widely
				disseminate acute care considerations for all muscular dystrophy populations.
				The care considerations should build upon existing efforts currently underway
				for congenital muscular dystrophy, fascioscapulohumeral muscular dystrophy,
				limb-girdle muscular dystrophy, and myotonic muscular dystrophy, and
				incorporate strategies specifically responding to the findings of the national
				transitions survey of minority, young adult and adult communities of muscular
				dystrophy
				patients.</text>
				</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


